Intracellular-delivery of a single-chain antibody against hepatitis B core protein via cell-penetrating peptide inhibits hepatitis B virus replication in vitro

Xun,Yunhao; Pan,Qingchun; Tang,Zhenghao; Chen,Xiaohua; Yu,Yongsheng; Xi,Min; Zang,Guoqing

doi:10.3892/ijmm.2012.1210

Intracellular-delivery of a single-chain antibody against hepatitis B core protein via cell-penetrating peptide inhibits hepatitis B virus replication in vitro

Authors:
- Yunhao Xun
- Qingchun Pan
- Zhenghao Tang
- Xiaohua Chen
- Yongsheng Yu
- Min Xi
- Guoqing Zang
View Affiliations

Affiliations: Department of Infectious Disease, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, P.R. China
Published online on: December 12, 2012 https://doi.org/10.3892/ijmm.2012.1210
Pages: 369-376

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Assembly of nucleocapsids is an attractive target for novel anti-hepatitis B virus (HBV) agents, and intracellular single-chain variable fragment (scFv) antibodies against HBV core (HBc) protein are a class of potential alternatives for this purpose; however, their application is limited by the lack of a suitable means of delivery. Owing to the favorable performance of cytoplasmic transduction peptide (CTP) in cargo delivery in hepatocytes, we purified an anti-HBc scFv fused to CTP using a previous screened sequence by a prokaryotic expression system and evaluated its efficacy in the inhibition of HBV in vitro. Our results showed that cytoplasmic translocation of the previous anti-HBc scFv was achieved by CTP in HepG2.2.15 cells. Immunoprecipitation analysis indicated the fusion protein anti-HBc scFv-CTP interacted with its target antigen HBc, and negligible cytotoxicity was observed. Moreover, the anti-HBc scFv-CTP interfered with nucleocapsid assembly and markedly reduced both the supernatant HBV DNA level and the intracellular DNA replication intermediates, with a 5.1 µM of half maximal effect concentration and a dose-dependent effect. In conclusion, this novel anti-HBc scFv fused to CTP demonstrated inhibitory activity of HBV replication in vitro and warrants further in vivo study.

View Figures

View References

1.	Zanetti AR, Van Damme P and Shouval D: The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 26:6266–6273. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Perrillo R: Benefits and risks of interferon therapy for hepatitis B. Hepatology. 49(Suppl 5): S103–S111. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Dienstag JL: Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 49(Suppl 5): S112–S121. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Snow-Lampart A, Chappell B, Curtis M, et al: No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 53:763–773. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Bingfa X, Qinglin F, Hui H, Canjun W, Wei W and Lihua S: Anti-hepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-alpha-2b fusion protein in vitro and in vivo. Pharmacology. 83:323–332. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Carey I and Harrison PM: Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 18:1655–1666. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Urban S, Schulze A, Dandri M and Petersen J: The replication cycle of hepatitis B virus. J Hepatol. 52:282–284. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Stein LL and Loomba R: Drug targets in hepatitis B virus infection. Infect Disord Drug Targets. 9:105–116. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Grimm D, Thimme R and Blum HE: HBV life cycle and novel drug targets. Hepatol Int. 5:644–653. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G and Dandri M: Control of cccDNA function in hepatitis B virus infection. J Hepatol. 51:581–592. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Katen SP, Chirapu SR, Finn MG and Zlotnick A: Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem Biol. 5:1125–1136. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Deres K, Schroder CH, Paessens A, et al: Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science. 299:893–896. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Shi C, Wu CQ, Cao AM, Sheng HZ, Yan XZ and Liao MY: NMR-spectroscopy-based metabonomic approach to the analysis of Bay41-4109, a novel anti-HBV compound, induced hepatotoxicity in rats. Toxicol Lett. 173:161–167. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Han J, Pan X, Gao Y and Weil L: Inhibition of hepatitis B virus replication by the internal fragment of hepatitis B core protein. Virus Res. 150:129–134. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Yamamoto M, Hayashi N, Takehara T, et al: Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Hepatology. 30:300–307. 1999. View Article : Google Scholar : PubMed/NCBI
16.	Jin YH, Hong SH, Kim K, Shin HJ and Park S: Intracellular antibody fragment against hepatitis B virus X protein does not inhibit viral replication. Yonsei Med J. 47:721–728. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Heng BC and Cao T: Making cell-permeable recombinant telomerase (trans-telomerase) through fusion of its catalytic subunit (hTERT) with protein transduction domains (PTD): a possible strategy to overcome replicative senescence during ex vivo culture of primary explanted cells. Med Hypotheses. 65:199–200. 2005.
18.	Gump JM and Dowdy SF: TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med. 13:443–448. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Zorko M and Langel U: Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev. 57:529–545. 2005. View Article : Google Scholar : PubMed/NCBI
20.	Doorbar J and Griffin H: Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opin Biol Ther. 7:677–689. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Fonseca SB, Pereira MP and Kelley SO: Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev. 61:953–964. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Chames P, Van Regenmortel M, Weiss E and Baty D: Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 157:220–233. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Pan XB, Wei L, Han JC, Ma H, Deng K and Cong X: Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production. Antiviral Res. 89:109–114. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Tang ZH, Ma HH, Chen WS, Gu L, Li G and Yao JL: Screening, identifying and sequencing of human single-chain variable fragment specific to hepatitis B virus core protein. Zhongguo Binglishengli Zazhi. 19:329–333. 2003.(In Chinese).
25.	Kim D, Jeon C, Kim JH, et al: Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res. 312:1277–1288. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Friguet B, Chaffotte AF, Djavadi-Ohaniance L and Goldberg ME: Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods. 77:305–319. 1985. View Article : Google Scholar : PubMed/NCBI
27.	Butz K, Denk C, Fitscher B, et al: Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene. 20:6579–6586. 2001. View Article : Google Scholar : PubMed/NCBI